Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.66
0.0000
Post-market: 6.57-0.0900-1.35%19:36 EDT
Volume:3.20M
Turnover:21.15M
Market Cap:2.34B
PE:-15.18
High:6.75
Open:6.70
Low:6.49
Close:6.66
52wk High:9.75
52wk Low:2.91
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.90
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:9.21
PE(LYR):-11.10

Loading ...

Nuvation Bio announces annual shareholder meeting via webcast

Reuters
·
Apr 10

Nuvation Bio Chief Regulatory Officer Kerry Wentworth disposes 200,000 shares for $903,560

Reuters
·
Apr 09

RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 08

JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 07

RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Nuvation Bio Inc : RBC Raises Target Price to $20 From $13

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?

Simply Wall St.
·
Apr 04

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 02

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Nuvation Bio acquires Japan rights to safusidenib from Daiichi Sankyo

Reuters
·
Apr 01

Nuvation Bio Inc - Buys Japan Rights to Safusidenib From Daiichi Sankyo

THOMSON REUTERS
·
Apr 01

Nuvation Bio Inc - Gains Ownership of Global Clinical Development Program for Safusidenib

THOMSON REUTERS
·
Apr 01

Nuvation Bio (NUVB) Receives a Buy from Wedbush

TIPRANKS
·
Mar 27

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Mar 27

March 2026's Promising Penny Stocks To Watch

Simply Wall St.
·
Mar 27

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

TIPRANKS
·
Mar 27

Nuvation Bio shares rise; EMA validates taletrectinib MAA for advanced ROS1+ NSCLC in Europe

Reuters
·
Mar 27

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

THOMSON REUTERS
·
Mar 27